Drug Manufacturing

Philip Morris to acquire inhaled drug provider Vectura Group for $1.2bn

Philip Morris International (PMI) has agreed to acquire British pharmaceutical firm Vectura Group for about $1.183bn (£852m) to expand its product pipeline development capabilities in inhaled therapeutics.

Verge Genomics, Eli Lilly partner to develop ALS therapies

Verge Genomics has announced a three-year partnership with Eli Lilly and Company to discover and develop novel therapies for amyotrophic lateral sclerosis (ALS), a motor neuron disease.

Mexico produces test batch of Sputnik V Covid-19 vaccine

The Russian Direct Investment Fund (RDIF) has announced the production of a test batch of the Russian Covid-19 vaccine, Sputnik V, in Mexico.

Philip Morris to acquire Fertin Pharma for $812.8m

Philip Morris International has signed an agreement to acquire Fertin Pharma from private equity firm EQT for approximately $812.8m (DKK5.1bn).

IFC announces $713m joint financing to Aspen to boost Covid-19 vaccine production

The International Finance Corporation (IFC) has announced a joint financing package of $712.67m (€600m) for Aspen Pharmacare to support the Covid-19 vaccines production.

GIC invests $1bn in Grifols’ subsidiary Biomat USA

Spanish healthcare company Grifols announced that Singapore's wealth fund GIC agreed to invest about $1bn in Grifols’ wholly owned US subsidiary Biomat USA.

Indivior, Aelis Farma partner to advance treatment for cannabis use disorder

Pharmaceutical company Indivior has collaborated with French biotechnology company Aelis Farma to advance the clinical development of a treatment for cannabis use disorder (CUD) and cannabis-induced psychosis (CIP).

Samsung Biologics reveals plans to add mRNA vaccine production line

South Korean drug manufacturer Samsung Biologics is planning to expand its portfolio of services by adding a mRNA vaccine drug substance (DS) manufacturing line at its facility in Songdo, Seoul.

CANbridge signs license agreement with Mirum for maralixibat in Greater China

Biopharmaceutical company CANbridge Pharmaceuticals has signed a licensing agreement with Mirum Pharmaceuticals for the development and commercialisation of maralixibat in Greater China.